



**Arkansas BlueCross BlueShield**

**Medical Oncology Code List**

**\*\*\*Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC code changes issued by CMS. Please contact Arkansas BlueCross BlueShield or eviCore, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed\*\*\***

Effective Date: 4/1/23

Description	Alt Descriptions	HCPCs Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
5-Fluorouracil- Injection	5FU, Adrucil	J9190	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Ado-Trastuzumab Emtansine	Kadcyla	J9354	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Aldesleukin	Proleukin, Interleukin-2	J9015	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Amivantamab-vmjw	Rybrevant	J9061	Primary	Medical Oncology - CHEMO	Y	01/01/22	N/A	J9061 - new code effective 1/1/22, replacing C9083, J9999
Aprepitant	Cinvanti	J0185	Supportive - Antiemetic	Medical Oncology - SPORT	Y	01/01/21	N/A	
Arsenic Trioxide	Trisenox	J9017	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Asparaginase	Erwinaze	J9019	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Asparaginase erwinia chrysanthemi (recombinant)-rywn	Rylaze	J9021	Primary	Medical Oncology - CHEMO	Y	01/01/22	N/A	J9021 - new code effective 1/1/22, replacing C9399, J9999
Atezolizumab	Tecentriq	J9022	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Avelumab	Bavencio	J9023	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Azacitidine	Vidaza	J9025	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
BCG	TheraCys, Tice	J9030	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Belantamab Mafodotin-blmf	Blenrep	J9037	Primary	Medical Oncology - CHEMO	Y	04/01/21	N/A	J9037- new code effective 04/01/21
Belinostat	Beleodaq	J9032	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bendamustine HCL	Belrapzo	J9036	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bendamustine HCL	Bendeka	J9034	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bendamustine hcl	Treanda	J9033	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bevacizumab	Avastin	J9035	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bevacizumab (Radiation Necrosis)	Avastin	J9035	Supportive	Medical Oncology - SPORT	Y	06/04/22	N/A	Supportive pathway for the use of Avastin to treat Radiation Induced Necrosis of the CNS
Bevacizumab-adcd	Vegzelma	Q5129	Primary	Medical Oncology - CHEMO	Y	10/05/22	N/A	New permanent HCPC Code: Q5129 effective: 04/01/2023.

Effective Date: 4/1/23

Description	Alt Descriptions	HCPs Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
Bevacizumab-adcd	Vegzelma	C9399	Primary	Medical Oncology - CHEMO	Y	10/05/22	N/A	New drug effective 10/5/22, may not be available on market until early 2023
Bevacizumab-adcd	Vegzelma	J9999	Primary	Medical Oncology - CHEMO	Y	10/05/22	N/A	New drug effective 10/5/22, may not be available on market until early 2023
Bevacizumab-awwb	Mvasi	Q5107	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bevacizumab-awwb (Radiation Necrosis)	Mvasi	Q5107	Supportive	Medical Oncology - SPORT	Y	06/04/22	N/A	Supportive pathway for the use of Mvasi to treat Radiation Induced Necrosis of the CNS
Bevacizumab-bvzr	Zirabev	Q5118	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bevacizumab-bvzr (Radiation Necrosis)	Zirabev	Q5118	Supportive	Medical Oncology - SPORT	Y	06/04/22	N/A	Supportive pathway for the use of Zirabev to treat Radiation Induced Necrosis of the CNS
Bleomycin	Blenoxane	J9040	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Blinatumomab	Blincyto	J9039	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bortezomib	Velcade	J9041	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Bortezomib (Dr. Reddy's)	Bortezomib (Dr. Reddy's)	J9046	Primary	Medical Oncology - CHEMO	Y	01/01/23	N/A	J9046 New code for existing drug to include manufacturer name effective 1/1/23
Bortezomib (Fresenius Kabi)	Bortezomib (Fresenius Kabi)	J9048	Primary	Medical Oncology - CHEMO	Y	01/01/23	N/A	J9048 New code for existing drug to include manufacturer name effective 1/1/23
Bortezomib (Hospira)	Bortezomib (Hospira)	J9049	Primary	Medical Oncology - CHEMO	Y	01/01/23	N/A	J9049 New code for existing drug to include manufacturer name effective 1/1/23
Brentuximab Vedotin	Adcetris	J9042	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Burosumab-twza	Crysvita	J0584	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	New drug - 7/3/20
Cabazitaxel	Jevtana	J9043	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Calaspargase pegol-mknl	Asparlas	J9118	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Capecitabine - oral	Xeloda (150 mg)	J8520	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	Medicare Part B
Capecitabine - oral	Xeloda (500 mg)	J8521	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	Medicare Part B
Carboplatin	Paraplatin	J9045	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Carfilzomib	Kyprolis	J9047	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Carmustine	BICNU, BCNU	J9050	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Cemiplimab-rlwc	Libtayo	J9119	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Cetuximab	Erbix	J9055	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Cisplatin	Platinol	J9060	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Cladribine	Leustatin	J9065	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Clofarabine	Clolar	J9027	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Copanlisib	Aliqopa	J9057	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Cyclophosphamide - inj	Cytoxan, Endoxan-Asta	J9070	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Cyclophosphamide - inj (auromedic)	Cyclophosphamide - inj (auromedics) 10 mg	J9071	Primary	Medical Oncology - CHEMO	Y	04/01/22	N/A	J9071 - new code effective 4/1/22 replacing C9087

Effective Date: 4/1/23

Description	Alt Descriptions	HCPs Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
Cytarabine	Ara-C	J9100	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Cytarabine-Liposome	DepoCyt	J9098	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Dacarbazine	DTIC-Dome	J9130	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Daunorubicin	Cosmegen, Actinomycin	J9120	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Daratumumab	Darzalex	J9145	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Daratumumab and hyaluronidase-fihj	Darzalex Faspro	J9144	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	J9144 - new code effective 1/1/21
Darbepoetin alfa	Aranesp	J0881	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Daunorubicin	Cerubidine	J9150	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Decitabine	Dacogen	J0894	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Degarelix	Firmagon	J9155	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Denosumab	Xgeva, Prolia	J0897	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Dinutuximab	Unituxin	J9999	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Docetaxel	Taxotere	J9171	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Dostarlimab-gxty	Jemperli	J9272	Primary	Medical Oncology - CHEMO	Y	01/01/22	N/A	J9272 - new code effective 1/1/22, replacing C9082, J9999
Doxorubicin HCL	Adriamycin	J9000	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Doxorubicin HCL (liposomal)	Doxil, Doxorubicin HCL (Liposomal) not otherwise specified	Q2050	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Durvalumab	Imfinzi	J9173	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Eflapegrastim-xnst	Rolvedon	J1449	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	New permanent HCPC Code: J1449, effective: 04/01/2023.
Eflapegrastim-xnst	Rolvedon	C9399	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	New drug effective 10/5/22, may not be available on market until 4th quarter 2022
Eflapegrastim-xnst	Rolvedon	J3590	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	New drug effective 10/5/22, may not be available on market until 4th quarter 2022
Elotuzumab	Empliciti	J9176	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Enfortumab vedotin-ejfv	Padcev	J9177	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	J9177 - New code effective 7/1/20
Epirubicin	Ellence	J9178	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Epoetin alfa	Epogen, Procrit	J0885	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Epoetin alfa-epbx	Retacrit	Q5106	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Eribulin mesylate	Halaven	J9179	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Etoposide - inj	Toposar, VePesid, Etopophos	J9181	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Etoposide - oral	Toposar	J8560	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	Medicare Part B
Fam-trastuzumab deruxtecan-nxki	Enhertu	J9358	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	J9358 - New code effective 7/1/20
Filgrastim	Neupogen	J1442	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	

Effective Date: 4/1/23

Description	Alt Descriptions	HCPCS Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
Filgrastim-aafi	Nivestym	Q5110	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Filgrastim-ayow	Releuko	Q5125	Supportive	Medical Oncology - SPORT	Y	10/01/22	N/A	Q5125 - new code effective 10/1/22 replacing C9096 and J9999
Filgrastim-sndz	Zarxio	Q5101	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Floxuridine	FUDR	J9200	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Fludarabine Phosphate	Fludara, Oforta	J9185	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Fosaprepitant	Emend	J1453	Supportive - Antiemetic	Medical Oncology - SPORT	Y	01/01/21	N/A	
Fosnetupitant/Palonosetron	Akynzeo	J1454	Supportive - Antiemetic	Medical Oncology - SPORT	Y	01/01/21	N/A	
Fulvestrant	Faslodex	J9395	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Gemcitabine	Gemzar	J9201	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Gemcitabine HCL in NaCL	Infugem	J9198	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	J9198 - New code effective 7/1/20
Gemtuzumab Ozogamicin	Mylotarg	J9203	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Goserelin acetate implant	Zoladex	J9202	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Granisetron - subcutaneous	Sustol	J1627	Supportive - Antiemetic	Medical Oncology - SPORT	Y	01/01/21	N/A	
Histrelin Implant	Vantas	J9225	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Idarubicin HCL - inj	Idamycin	J9211	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Ifosfamide	Ifex, Mitoxana	J9208	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Injection, gemcitabine hydrochloride (accord)	Injection, gemcitabine hydrochloride (accord)	J9196	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	HCPC Code: J9196 - effective 4/1/23; Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201, 200 mg
Inotuzumab Ozogamicin	Besponsa	J9229	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Interferon, alfa-2b, recombinant	Intron A	J9214	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Interferon, gamma-1b	Actimmune	J9216	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Ipilimumab	Yervoy	J9228	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Irinotecan	Camptosar	J9206	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Irinotecan Liposome	Onivyde	J9205	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Ixabepilone	Ixempra	J9207	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Lanreotide	Somatuline Depot	J1930	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Lanreotide (Cipla)	Lanreotide (Cipla)	J1932	Primary	Medical Oncology - CHEMO	Y	10/01/22	N/A	J1932 - new code effective 10/1/22 replacing J1930 (please note J1930 is still in effect for Lanreotide (Somatuline Depot))
Leucovorin - inj	Leucovorin	J0640	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Leuprolide Acetate (J1950: 3.75mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J1950	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Leuprolide Acetate (J9217: 7.5mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J9217	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	

Effective Date: 4/1/23

Description	Alt Descriptions	HCPs Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
Leuprolide Acetate (J9218: 1mg)	Lupron	J9218	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Leuprolide Mesylate	Camcevi	J1952	Primary	Medical Oncology - CHEMO	Y	01/01/22	N/A	J1952 - new code effective 1/1/22, replacing C9399, J9999
Levoleucovorin	Fusilev	J0641	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Levoleucovorin	Khapzory	J0642	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Liposome-encapsulated combination of Daunorubicin and Cytarabine	Vyxeos	J9153	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Loncastuximab tesirine-lpyl	Zynlonta	J9359	Primary	Medical Oncology - CHEMO	Y	04/01/22	N/A	J9359 - New code effective 4/1/22, replacing C9084 and J9999
Lurbinectedin	Zepzelca	J9223	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	J9223 - new code effective 1/1/21
Luspatercept-aamt	Reblozyl	J0896	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	J0896 - New code effective 7/1/20
Margetuximab-cmkb	Margenza	J9353	Primary	Medical Oncology - CHEMO	Y	07/01/21	N/A	J9353 - new code effective 7/1/21
Melphalan HCL - inj	Evomela	J9246	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	J9246 - New code effective 7/1/20
Melphalan HCL - NOS inj	Alkeran	J9245	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Mesna	Mesnex	J9209	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Methotrexate Sodium (J9250: 5mg)	Folex, Methotrexate	J9250	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Methotrexate Sodium (J9260: 50mg)	Folex, Methotrexate	J9260	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Mirvetuximab Soravtansine-gynx	Elahere	C9146	Primary	Medical Oncology - CHEMO	Y	11/22/22	N/A	New Code effective: 04/01/2023
Mirvetuximab Soravtansine-gynx	Elahere	C9399	Primary	Medical Oncology - CHEMO	Y	11/22/22	N/A	
Mirvetuximab Soravtansine-gynx	Elahere	J9999	Primary	Medical Oncology - CHEMO	Y	11/22/22	N/A	
Mitomycin	Jelmyto	J9281	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	J9281 - new code effective 1/1/21 - Medicare Part B
Mitomycin	Mutamycin	J9280	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Mitoxantrone HCL	Novantrone	J9293	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Mogamulizumab-kpkc	Poteligeo	J9204	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Mosunetuzumab-axgb	Lunsumio	C9399	Primary	Medical Oncology - CHEMO	Y	01/05/23	N/A	New drug 1/5/23
Mosunetuzumab-axgb	Lunsumio	J9999	Primary	Medical Oncology - CHEMO	Y	01/05/23	N/A	New drug 1/5/23
Moxetumomab pasudotox-tdfk	Lumoxiti	J9313	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Nadofaragen Firdenovec-vncg	Adstiladrin	C9399	Primary	Medical Oncology - CHEMO	Y	01/05/23	N/A	New drug 1/5/23
Nadofaragen Firdenovec-vncg	Adstiladrin	J9999	Primary	Medical Oncology - CHEMO	Y	01/05/23	N/A	New drug 1/5/23
Naxitamab-ggqk	Danyelza	J9348	Primary	Medical Oncology - CHEMO	Y	7/1/2021	N/A	J9348 - new code effective 7/1/21
Necitumumab	Portrazza	J9295	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Nelarabine	Arranon	J9261	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Nivolumab	Opdivo	J9299	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	

Effective Date: 4/1/23

Description	Alt Descriptions	HCPs Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
Nivolumab and Relatlimab-rmbw	Opdualag	J9298	Primary	Medical Oncology - CHEMO	Y	10/01/22	N/A	J9298 - new code effective 10/1/22 replacing C9399 and J9999
Obinutuzumab	Gazyva	J9301	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Octreotide depot	Sandostatin	J2353	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Octreotide non-depot	Sandostatin	J2354	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Ofatumumab	Arzerra	J9302	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Omacetaxine	Synribo	J9262	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Oxaliplatin	Eloxatin	J9263	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Paclitaxel	Nov-Onxol, Taxol	J9267	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Paclitaxel (albumin-bound)	Abraxane	J9264	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Palonosetron	Aloxi	J2469	Supportive - Antiemetic	Medical Oncology - SPORT	Y	01/01/21	N/A	
Pamidronate Disodium	Aredia	J2430	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Panitumumab	Vectibix	J9303	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Pegaspargase	Oncaspar	J9266	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta	J2506	Supportive	Medical Oncology - SPORT	Y	01/01/22	N/A	
Pegfilgrastim-appf	Nyvepria	Q5122	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	Q5122 - new code effective 1/1/21
Pegfilgrastim-bmez	Ziextenzo	Q5120	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	Q5120 - New code effective 7/1/20
Pegfilgrastim-cbqv	Udenyca	Q5111	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Pegfilgrastim-fpgk	Stimufend	Q5127	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	Permanent HCPC Code: Q5127 effective 04/01/2023
Pegfilgrastim-fpgk	Stimufend	C9399	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	New drug effective 10/5/22, may not be available on market until early 2023
Pegfilgrastim-fpgk	Stimufend	J3590	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	New drug effective 10/5/22, may not be available on market until early 2023
Pegfilgrastim-jmdb	Fulphila	Q5108	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Pegfilgrastim-pbbk	Flyntra	Q5130	Supportive	Medical Oncology - SPORT	Y	09/06/22	N/A	Permanent HCPC Code: Q5130, effective 04/01/2023.
Pegfilgrastim-pbbk	Flyntra	C9399	Supportive	Medical Oncology - SPORT	Y	09/06/22	N/A	New drug effective 9/6/22
Pegfilgrastim-pbbk	Flyntra	J3590	Supportive	Medical Oncology - SPORT	Y	09/06/22	N/A	New drug effective 9/6/22
Peginterferon, alfa-2a	Pegasys	J3590	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Peginterferon, alfa-2b	PegIntron	J3590	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Pembrolizumab	Keytruda	J9271	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Pemetrexed	Alimta, Pemetrexed not otherwise specified	J9305	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Pemetrexed	Pemfexy	J9304	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	New drug 10/1/20

Effective Date: 4/1/23

Description	Alt Descriptions	HCPCS Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
Pemetrexed (accord)	Pemetrexed (accord)	J9296	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	HCPC Code: J9296 effective: 04/01/2023. Injection, pemetrexed (accord) not therapeutically equivalent to J9305, 10 mg
Pemetrexed (hospira)	Pemetrexed (hospira)	J9294	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	HCPC Code: J9294 effective: 04/01/2023. Injection, pemetrexed (hospira) not therapeutically equivalent to J9305, 10 mg
Pemetrexed (sandoz)	Pemetrexed (sandoz)	J9297	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	HCPC Code: J9297 effective: 04/01/2023. Injection, pemetrexed (accord) not therapeutically equivalent to J9305, 10 mg
Pentostatin	Nipent	J9268	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Pertuzumab	Perjeta	J9306	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Pertuzumab / trastuzumab / hyaluronidase-zzxf	Phesgo	J9316	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	J9316 - new code effective 1/1/21
Polatuzumab vedotin-piiq	Polivy	J9309	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Porfimer Sodium	Photofrin	J9600	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Pralatrexate	Folotyn	J9307	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Ramucirumab	Cyramza	J9308	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Rituximab	Rituxan	J9312	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Rituximab and Hyaluronidase Human	Rituxan Hycela	J9311	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Rituximab-abbs	Truxima	Q5115	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Rituximab-arrx	Riabni	Q5123	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	Q5123 - new code effective 7/1/21
Rituximab-pvvr	Ruxience	Q5119	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	Q5119 - New code effective 7/1/20
Romidepsin (lyophilized)	Istodax	J9319	Primary	Medical Oncology - CHEMO	Y	10/01/21	N/A	J9319 - new code effective 10/1/21
Romidepsin (non-lyophilized)	Romidepsin, non-lyophilized	J9318	Primary	Medical Oncology - CHEMO	Y	10/01/21	N/A	J9318 - new code effective 10/1/21
Ropeginterferon alfa-2b-njft	Besremi	C9399	Primary	Medical Oncology - CHEMO	Y	12/02/21	N/A	New drug - 12/2/21
Ropeginterferon alfa-2b-njft	Besremi	J9999	Primary	Medical Oncology - CHEMO	Y	12/02/21	N/A	New drug - 12/2/21
Sargramostim	Leukine	J2820	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Siltuximab	Sylvant	J2860	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Sipuleucel-T	Provenge	Q2043	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Sirolimus protein-bound particles for injectable suspension (albumin bound)	Fyarro	J9331	Primary	Medical Oncology - CHEMO	Y	12/02/21	N/A	J9331 - new code effective 7/1/22 replacing C9091 and J9999
Sodium Thiosulfate Injection	Pedmark	J0208	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	New permanent HCPC Code: J1449, effective: 04/01/2023.
Sodium Thiosulfate Injection	Pedmark	C9399	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	New drug effective 10/5/22, may not be available on market until 4th quarter 2022
Sodium Thiosulfate Injection	Pedmark	J3490	Supportive	Medical Oncology - SPORT	Y	10/05/22	N/A	New drug effective 10/5/22, may not be available on market until 4th quarter 2022

Effective Date: 4/1/23

Description	Alt Descriptions	HCPs Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
Streptozocin	Zanosar	J9320	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Tafasitamab-cxix	Monjuvi	J9349	Primary	Medical Oncology - CHEMO	Y	04/01/21	N/A	J9349 - new code effective 04/01/21
Tagraxofusp-erzs	Elzonris	J9269	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Talimogene Laherparepvec	Imlygic	J9325	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Tbo-filgrastim	Granix	J1447	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	
Tebentafusp-tebn	Kimtrak	J9274	Primary	Medical Oncology - CHEMO	Y	10/01/22	N/A	J9274 - New code effective 10/1/22 replacing C9095 and J9999
Teclistamab-cqyv	Tecvayli	C9148	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Teclistamab-cqyv	Tecvayli	C9399	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Teclistamab-cqyv	Tecvayli	J3490	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Teclistamab-cqyv	Tecvayli	J3590	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Teclistamab-cqyv	Tecvayli	J9999	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Temozolomide - inj	Temodar	J9328	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Temozolomide - oral	Temodar	J8700	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	Medicare Part B
Temsirolimus	Torisel	J9330	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Teniposide	Vumon	Q2017	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Thiotepa	Thioplex	J9340	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Tisotumab vedotin-tftv	Tivdak	J9273	Primary	Medical Oncology - CHEMO	Y	04/01/22	N/A	J9273 - new code effective 4/1/22 replacing C9399 and J9999
Tocilizumab	Actemra	J3262	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Topotecan - inj	Hycamtin	J9351	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Trabectedin	Yondelis	J9352	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Trastuzumab	Herceptin	J9355	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Trastuzumab and hyaluronidase-oysk	Herceptin Hylecta	J9356	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Trastuzumab-anns	Kanjinti	Q5117	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Trastuzumab-dkst	Ogivri	Q5114	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Trastuzumab-dttb	Ontruzant	Q5112	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Trastuzumab-pkrb	Herzuma	Q5113	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Trastuzumab-qyyp	Trazimera	Q5116	Primary - Biosimilar	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Tremelimumab-actl	Imjudo	C9147	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Tremelimumab-actl	Imjudo	C9399	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Tremelimumab-actl	Imjudo	J3490	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Tremelimumab-actl	Imjudo	J3590	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22



Effective Date: 4/1/23

Description	Alt Descriptions	HCPCS Code	Drug Class	Program	Arkansas BCBS	Arkansas BCBS Effective Date	Arkansas BCBS Termination Date	Drug Comments
Tremelimumab-actl	Imjudo	J9999	Primary	Medical Oncology - CHEMO	Y	11/02/22	N/A	New Drug effective 11/2/22
Trilaciclib	Cosela	J1448	Supportive	Medical Oncology - SPORT	Y	10/01/21	N/A	J1448 - New code effective 10/1/21
Triptorelin Pamoate	Trelstar	J3315	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Valrubicin	Valstar	J9357	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Vinblastine Sulfate	Velban	J9360	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Vincristine Sulfate	Oncovin, Vincasar PFS	J9370	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Vincristine Sulfate Liposome	Marqibo	J9371	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Vinorelbine Tartrate	Navelbine	J9390	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Zivafibercept	Zaltrap	J9400	Primary	Medical Oncology - CHEMO	Y	01/01/21	N/A	
Zoledronic Acid	Zoledronic Acid	J3489	Supportive	Medical Oncology - SPORT	Y	01/01/21	N/A	